FARN — Faron Pharmaceuticals Oy Income Statement
0.000.00%
Last trade - 00:00- £225.44m
- £227.66m
Annual income statement for Faron Pharmaceuticals Oy, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 16.7 | 21.1 | 27.4 | 28.6 | 18.7 |
| Operating Profit | -16.7 | -21.1 | -27.4 | -28.6 | -18.7 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -16.9 | -21.2 | -28.7 | -30.9 | -25.9 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -16.9 | -21.2 | -28.7 | -30.9 | -25.9 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -16.9 | -21.2 | -28.7 | -30.9 | -25.9 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -16.9 | -21.2 | -28.7 | -30.9 | -25.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.26 | -0.293 | -0.365 | -0.334 | -0.293 |
| Dividends per Share |